1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,300 | 11,600 | 06.06. | |
| 11,300 | 11,600 | 05.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology | 1 | GlobeNewswire (USA) | ||
| 11.05. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.04. | Elicio Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 16.04. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 1 | GlobeNewswire (USA) | ||
| 25.03. | BayWa r.e, Elicio and BW Ideol open Buchan hub | 65 | reNews | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 4 | GlobeNewswire (USA) | ||
| 16.03. | Elicio Therapeutics kündigt "At-the-Market"-Aktienprogramm im Volumen von 100 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 12.03. | Elicio Therapeutics reports FY GAAP EPS of -$2.58 | 2 | Seeking Alpha | ||
| 12.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating | 1 | Investing.com | ||
| 09.03. | Rodman & Renshaw startet Coverage für Elicio Therapeutics mit Kaufempfehlung | 3 | Investing.com Deutsch | ||
| 18.02. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 8 | GlobeNewswire (USA) | ||
| 16.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 10 | GlobeNewswire (USA) | ||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 495 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 254 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 291 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 269 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,855 | +2,77 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
01.06.2026 / 09:43... ► Artikel lesen | |
| OCUGEN | 1,118 | +0,18 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 24,650 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,620 | +1,25 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOCRYST PHARMACEUTICALS | 7,232 | -0,85 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders | Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing... ► Artikel lesen | |
| IBIO | 1,744 | +10,10 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,690 | +0,27 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| REDHILL BIOPHARMA | 1,020 | -0,97 % | RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma... ► Artikel lesen | |
| MANNKIND | 2,978 | +1,09 % | MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF | Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,350 | +2,66 % | Cardiff Oncology meldet positive Phase-2-Studienergebnisse für Onvansertib | ||
| ALDEYRA | 1,530 | +8,51 % | Aldeyra Therapeutics: Aufsichtsratsmitglied Martin J. Joyce tritt nicht zur Wiederwahl an | ||
| TRAWS PHARMA | 1,380 | +0,73 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,323 | +5,50 % | Aktionäre von Coherus Oncology stimmen für Direktorenwahl und Änderungen am Eigenkapital-Plan |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,600 (+5,22 %) liegt der Kurs bei 12,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.